Laura G. Hansen
Investor Relations Contact presso DENALI THERAPEUTICS INC.
Profilo
Laura G.
Hansen occupies the position of Vice President-Investor Relations for Denali Therapeutics, Inc.
In the past she occupied the position of Director-Corporate Communications at FibroGen, Inc., Vice President-Corporate Affairs at BlackThorn Therapeutics, Inc., Director-Corporate Communications at Corvas International, Inc., Senior Director-Corporate Communications at Threshold Pharmaceuticals, Inc. and Vice President-Investor Relations of Aimmune Therapeutics, Inc.
She received a doctorate and an undergraduate degree from The University of Texas at Austin.
Posizioni attive di Laura G. Hansen
Società | Posizione | Inizio |
---|---|---|
DENALI THERAPEUTICS INC. | Investor Relations Contact | - |
Precedenti posizioni note di Laura G. Hansen
Società | Posizione | Fine |
---|---|---|
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/09/2020 |
AIMMUNE THERAPEUTICS, INC. | Investor Relations Contact | 01/03/2019 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Investor Relations Contact | 01/02/2016 |
FIBROGEN, INC. | Public Communications Contact | 01/07/2012 |
Corvas International, Inc. | Public Communications Contact | 01/07/2002 |
Formazione di Laura G. Hansen
The University of Texas at Austin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
FIBROGEN, INC. | Health Technology |
DENALI THERAPEUTICS INC. | Health Technology |
Aziende private | 4 |
---|---|
Corvas International, Inc. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Health Technology |